Analyst Upgrades: Facebook, Cyberark Software, bluebird bio

Analysts upwardly revised their ratings on Facebook Inc (FB), Cyberark Software Ltd (CYBR), and bluebird bio Inc (BLUE)

Mar 23, 2015 at 9:25 AM
facebook twitter linkedin


Analysts are weighing in today on social network giant Facebook Inc (NASDAQ:FB), cybersecurity firm Cyberark Software Ltd (NASDAQ:CYBR), and drugmaker bluebird bio Inc (NASDAQ:BLUE). Here's a quick roundup of today's bullish brokerage notes on FB, CYBR, and BLUE.

  • It's been a record-setting run for FB of late, and the equity looks ready to extend this momentum today, after receiving price-target hikes from JMP Securities (by $3 to $97) and Piper Jaffray (by $8 to $92) -- both in territory yet to be charted. Longer term, shares of FB are up roughly 25% year-over-year, and closed Friday at $83.80. Options traders, meanwhile, have shown a distinct preference for calls over puts in recent months. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Facebook Inc's 50-day call/put volume ratio of 2.57 ranks in the 90th annual percentile.

  • CYBR is 3.8% higher in electronic trading, thanks to an upbeat "buy" initiation from BofA-Merrill Lynch, and $60 price target -- representing expected upside of 23.2% to Friday's settlement at $48.69. This optimism shouldn't be too surprising, considering the stock has tacked on almost 23% year-to-date, but isn't shared throughout the brokerage bunch. Specifically, five out of seven analysts maintain a "hold" or worse recommendation on Cyberark Software Ltd, while the average 12-month price target of $46.88 stands at a discount to current trading levels.

  • BLUE has put in a tremendous showing on the charts, surging nearly fivefold over the past 52 weeks to trade at $124.76. Roth Capital thinks there's more room to run, and upped its price target on the stock to $145 from $120 -- in record-high waters. Elsewhere on the Street, however, skepticism has been growing. At the ISE, CBOE, and PHLX, BLUE's 10-day put/call volume ratio of 1.94 indicates nearly two puts have been bought to open for every call over the last two weeks. Plus, short interest jumped 10.9% in the last two reporting periods, and now accounts for a healthy 7.7% of the stock's available float. In fact, it would take more than a week to cover these shorted shares, at average daily trading levels. Should bluebird bio Inc continue its upward trajectory, a capitulation of some of the weaker bearish hands could translate into a fresh burst of buying power for BLUE.
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners